Enlivex Issues Urgent Statement on Fraudulent News Dissemination
Enlivex Therapeutics (ENLV) has issued an urgent statement addressing false information published by Tipranks.com claiming the company had suspended stock trading due to an internal investigation. The company strongly denies these claims, confirming that its shares continue to trade normally on both the Tel Aviv Stock Exchange and NASDAQ without interruption.
CEO Oren Hershkovitz characterized the incident as a deliberate attempt to manipulate public perception and mislead investors. The company plans to pursue legal action against those responsible, including the publishers and the hosting service of Tipranks.com. Enlivex maintains that it continues to execute its operating plan, focusing on developing AllocetraTM for osteoarthritis treatment.
Enlivex Therapeutics (ENLV) ha emesso una dichiarazione urgente per affrontare le false informazioni pubblicate da Tipranks.com, secondo cui la società avrebbe sospeso le negoziazioni azionarie a causa di un'indagine interna. L'azienda smentisce fermamente queste affermazioni, confermando che le sue azioni continuano a essere scambiate normalmente sia sulla Borsa di Tel Aviv che sul NASDAQ senza interruzioni.
Il CEO Oren Hershkovitz ha caratterizzato l'incidente come un tentativo deliberato di manipolare la percezione pubblica e fuorviare gli investitori. L'azienda prevede di intraprendere azioni legali contro i responsabili, inclusi gli editori e il servizio di hosting di Tipranks.com. Enlivex sostiene di continuare a eseguire il proprio piano operativo, concentrandosi sullo sviluppo di AllocetraTM per il trattamento dell'osteoartrite.
Enlivex Therapeutics (ENLV) ha emitido una declaración urgente abordando la información falsa publicada por Tipranks.com que afirmaba que la compañía había suspendido la negociación de acciones debido a una investigación interna. La empresa niega rotundamente estas afirmaciones, confirmando que sus acciones continúan negociándose normalmente tanto en la Bolsa de Tel Aviv como en el NASDAQ sin interrupciones.
El CEO Oren Hershkovitz caracterizó el incidente como un intento deliberado de manipular la percepción pública y engañar a los inversores. La compañía planea tomar acciones legales contra los responsables, incluidos los editores y el servicio de alojamiento de Tipranks.com. Enlivex mantiene que continúa ejecutando su plan operativo, centrándose en el desarrollo de AllocetraTM para el tratamiento de la osteoartritis.
Enlivex Therapeutics (ENLV)는 Tipranks.com에 의해 발표된 잘못된 정보에 대해 긴급 성명을 발표했습니다. 이 정보는 회사가 내부 조사를 이유로 주식 거래를 중단했다고 주장하고 있습니다. 회사는 이러한 주장을 강력히 부인하며, 텔아비브 증권 거래소와 NASDAQ에서 주식이 정상적으로 거래되고 있다고 확인했습니다.
CEO 오렌 헤르시코비츠는 이 사건을 공공 인식을 조작하고 투자자를 오도하려는 고의적인 시도로 묘사했습니다. 회사는 Tipranks.com의 발행인 및 호스팅 서비스에 대해 법적 조치를 취할 계획입니다. Enlivex는 골관절염 치료를 위한 AllocetraTM 개발에 집중하며 운영 계획을 계속 실행하고 있다고 주장합니다.
Enlivex Therapeutics (ENLV) a publié une déclaration urgente pour répondre à de fausses informations publiées par Tipranks.com, affirmant que la société avait suspendu le trading des actions en raison d'une enquête interne. L'entreprise dément fermement ces allégations, confirmant que ses actions continuent d'être échangées normalement à la fois sur la Bourse de Tel Aviv et sur le NASDAQ sans interruption.
Le PDG Oren Hershkovitz a qualifié l'incident de tentative délibérée de manipuler la perception publique et de tromper les investisseurs. La société prévoit d'intenter des poursuites judiciaires contre les responsables, y compris les éditeurs et le service d'hébergement de Tipranks.com. Enlivex maintient qu'elle continue d'exécuter son plan opérationnel, en se concentrant sur le développement d'AllocetraTM pour le traitement de l'ostéoarthrite.
Enlivex Therapeutics (ENLV) hat eine dringende Erklärung abgegeben, um falsche Informationen zu widerlegen, die von Tipranks.com veröffentlicht wurden und behaupten, das Unternehmen habe den Aktienhandel aufgrund einer internen Untersuchung ausgesetzt. Das Unternehmen weist diese Behauptungen entschieden zurück und bestätigt, dass seine Aktien sowohl an der Börse Tel Aviv als auch an der NASDAQ ohne Unterbrechung normal gehandelt werden.
CEO Oren Hershkovitz bezeichnete den Vorfall als einen absichtlichen Versuch, die öffentliche Wahrnehmung zu manipulieren und Investoren in die Irre zu führen. Das Unternehmen plant, rechtliche Schritte gegen die Verantwortlichen einzuleiten, einschließlich der Herausgeber und des Hosting-Dienstes von Tipranks.com. Enlivex betont, dass es weiterhin seinen Betriebsplan umsetzt und sich auf die Entwicklung von AllocetraTM zur Behandlung von Osteoarthritis konzentriert.
- Company maintains normal operations and trading status on both NASDAQ and TASE
- Taking decisive legal action against false information publishers
- Company subject to potentially damaging false market information
- Potential short-term market volatility due to misleading reports
Insights
This incident represents a serious attempt at market manipulation targeting Enlivex Therapeutics, a small-cap biotech company particularly vulnerable to such attacks due to its market capitalization of
- Immediate and unequivocal denial of false claims
- Clear communication through official channels
- Commitment to legal action against perpetrators
The targeting of Enlivex through Tipranks.com, a typically reputable financial platform, reveals an evolving sophistication in market manipulation tactics. Small-cap companies are particularly susceptible to such attacks due to lower trading volumes and increased price sensitivity to news.
From a legal perspective, this incident likely violates multiple securities laws, including Section 9(a)(4) of the Securities Exchange Act, which prohibits false or misleading statements about securities. The company's mention of pursuing legal action serves dual purposes: deterring future attempts and reassuring investors about management's commitment to protecting shareholder interests.
The incident underscores the critical importance of information verification in modern financial markets. Investors should note several key protective measures:
- Verify news through official SEC filings (Form 8-K for material events)
- Cross-reference company statements across multiple official channels
- Be particularly vigilant with small-cap stocks, which are more vulnerable to manipulation
The company's emphasis on its ongoing operations and AllocetraTM development suggests confidence in its fundamental business trajectory despite this attempt at market disruption. This transparent communication strategy, combined with the CEO's direct statement and provision of CFO contact information, represents strong corporate governance practices during crisis situations.
Ness-Ziona, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq and TASE: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, alerts investors and the public that a completely false and misleading report regarding the Company was intentionally published this morning by the website Tipranks.com claiming that the Company has suspended its stock trading due to an internal investigation. These reports are completely unfounded and constitute fake news. The Company continues to operate normally, and its shares continue to trade regularly on the Tel Aviv Stock Exchange and NASDAQ Stock Exchange without any interruption.
The Company unequivocally denies the claims made in this false report and urges investors to rely only on official communications from the Company, including press releases, filings with the U.S. Securities and Exchange Commission, and statements from verified Company channels.
“This is a blatant attempt to manipulate public perception and mislead investors,” said Oren Hershkovitz, the Company’s CEO. “We take this matter very seriously and will pursue all available legal actions against the individuals responsible, including the publishers of the false report and the hosting service of Tipranks.com. We are continuing to execute our operating plan and are excited about the potential of AllocetraTM to offer treatment solutions to tens of millions of osteoarthritis patients, who have very poor treatment alternatives today.”
Investors and stakeholders with concerns or questions are encouraged to contact Shachar Shlosberger, the Company’s CFO.
ABOUT ENLIVEX
Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. For more information, visit http://www.enlivex.com.
Safe Harbor Statement: This press release contains forward-looking statements, which may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would”, “could,” “intends,” “estimates,” “suggests,” “has the potential to” and other words of similar meaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRATM programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex’s business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRATM product line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Enlivex’s filings with the Securities and Exchange Commission, including in the Company’s most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.
ENLIVEX CONTACT
Shachar Shlosberger, CFO
Enlivex Therapeutics, Ltd.
shachar@enlivexpharm.com
INVESTOR RELATIONS CONTACT
Dave Gentry, CEO
RedChip Companies Inc.
1-407-644-4256
ENLV@redchip.com
FAQ
Has ENLV stock trading been suspended as claimed by Tipranks.com?
What legal actions is ENLV taking regarding the false trading suspension claims?
What is the current status of ENLV's operations following the false report?
How can ENLV investors verify authentic company information?
